Advanced therapy medicinal products — ATMPs — have moved out of the clinical trial press release and into routine NHS tertiary care. There are now licensed CAR-T therapies for lymphoma and leukaemia, a gene therapy for spinal muscular atrophy, a one-off treatment for a rare eye condition and several approved regenerative medicines. Community pharmacy does not supply these products directly, but increasingly meets patients on aftercare pathways. This primer explains what the category is and where it touches day-to-day practice.
The three ATMP categories
The MHRA recognises three types of advanced therapy medicinal product, mirroring EU regulation:
- Gene therapy medicinal products (GTMPs) — contain recombinant nucleic acids intended to modify a gene sequence or its expression. Examples: Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, Luxturna (voretigene neparvovec) for inherited retinal dystrophy, Casgevy (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassaemia.
- Somatic cell therapy medicinal products (sCTMPs) — contain cells or tissues that have been substantially manipulated, or used for a different function than in the donor. Examples: autologous cultured chondrocytes, some dendritic cell vaccines.
- Tissue-engineered products (TEPs) — contain engineered cells or tissues that repair, regenerate or replace human tissue. Examples: Holoclar for limbal stem cell deficiency.
CAR-T cell therapies — Kymriah, Yescarta, Tecartus, Breyanzi, Abecma — are classified as gene therapy medicinal products because of the genetic modification of the autologous T cells.
Regulation in the UK
ATMPs are centrally regulated by the MHRA under the Human Medicines Regulations 2012, with technical requirements aligned with the EMA's 1394/2007 regulation. Manufacturing and release are covered by Good Manufacturing Practice (GMP) Part IV, the ATMP-specific annex, and the Human Tissue Authority licences any starting-material tissue work.
Each ATMP is assessed by NICE as a health technology appraisal. The Highly Specialised Technologies programme handles ultra-rare conditions — Zolgensma, Libmeldy (metachromatic leukodystrophy) and Casgevy have all gone through that route — while standard Technology Appraisal handles more common indications.
Dispensing is restricted to named NHS Treatment Centres with the necessary infrastructure: GMP-compliant cell handling, apheresis where autologous cells are required, intensive care backup, and multidisciplinary teams across haematology, neurology, ophthalmology or the relevant specialty.
What this means for community pharmacy
Community pharmacy never holds or supplies ATMP products. But three touchpoints are becoming routine.
1. Post-infusion monitoring medicines. CAR-T patients return to their communities on complex medicines regimens — antivirals (valaciclovir, letermovir), antibacterial prophylaxis (co-trimoxazole), occasionally antifungals, immunoglobulin replacement, and PPIs or antiemetics for residual GI symptoms. The pharmacy team is often the first to notice adherence issues, adverse reactions or drug interactions with new medicines.
2. Medicines reconciliation for rare-disease patients. Zolgensma-treated children with spinal muscular atrophy continue on nusinersen or risdiplam; paediatric formulation queries frequently land in community pharmacy. Luxturna-treated patients need periodic ophthalmic aftercare and topical steroids. Knowing the product exists and that the indication is usually life-long changes the tone of the consultation.
3. Public-interest questions. When a CAR-T or gene therapy makes national news, customers often ask pharmacy teams whether the treatment applies to them or a family member. A clear, non-alarming answer — that these are centrally-commissioned, tertiary-centre therapies accessed through specialist referral — is more useful than a technical detail.
Typical aftercare medicines to recognise
| Therapy | Likely aftercare medicines in community |
|---|---|
| CAR-T (lymphoma / leukaemia) | Aciclovir/valaciclovir, co-trimoxazole, immunoglobulin (hospital-supplied), PPIs |
| Gene therapy for SMA (Zolgensma) | Prednisolone taper post-infusion; ongoing nusinersen or risdiplam |
| Luxturna (inherited retinal dystrophy) | Topical and oral steroids for 4 weeks post-procedure |
| Holoclar (limbal stem cell deficiency) | Topical steroids, preservative-free eye drops |
| Casgevy (sickle cell, beta thalassaemia) | Fertility preservation medicines pre-treatment; supportive medicines post |
A medicines list that contains any of these alongside a tertiary-centre follow-up letter is a flag that a full reconciliation is worth prioritising.
Yellow Card and adverse events
ATMP adverse reactions — especially immune-related events, graft-versus-host disease, cytokine release syndrome symptoms presenting late, persistent cytopenias — are reportable via the MHRA's Yellow Card scheme. Community pharmacy teams who suspect a serious adverse reaction in an ATMP-treated patient should report both to the treating centre and via Yellow Card. Reporting thresholds for ATMPs are deliberately low given the small post-authorisation safety populations.
Cost and access context
ATMPs are among the most expensive medicines the NHS commissions. Zolgensma was approved at a list price above £1.7 million per dose (with a confidential NHS discount). Casgevy sits at a similar list level. NICE's Highly Specialised Technologies framework uses managed access agreements to balance cost with real-world evidence collection — several current ATMPs remain within their data collection periods.
This matters for pharmacy because patients frequently have questions about eligibility, waiting lists and why a specific therapy is or is not offered for their condition. A brief understanding of the centralised pathway and NICE role is more valuable than product-specific detail.
Where this sits in UK pharmacy
ATMP aftercare is already present in community pharmacy and will expand as more approvals land. PharmSee's pharmacy directory maps the UK contractor network supporting these pathways, and our clinical pharmacy jobs show growing employer demand for pharmacists confident at the intersection of specialist medicines and primary care.
Caveats
This primer summarises MHRA, EMA and NICE positions as of April 2026. Product availability, indications and managed access agreements change frequently; always check the MHRA product register and NICE's latest technology appraisal before counselling a specific patient. Nothing in this piece substitutes for the tertiary centre's treatment plan.